X-Sympa-To: bioinfo@impg.prd.fr
Return-Path: <annerezo@gmail.com>
X-Original-To: bioinfo@sfbi.fr
Delivered-To: bioinfo@localhost
Received: from a1.relay.syrhano.net (a1.relay.syrhano.net [193.52.218.20])
	by asso.crihan.fr (Postfix) with ESMTP id 4C44C26801D
	for <bioinfo@sfbi.fr>; Fri, 25 Apr 2014 12:58:17 +0200 (CEST)
X-IronPort-Anti-Spam-Filtered: true
X-IronPort-Anti-Spam-Result: AkIFANI+WlPRVcCulGdsb2JhbABZg1VXghxJwTQEgQoIFg4BAQEBBwsLCRIqgjgXHQEsAwEJAw0FAw0PAiYCJBIBBQERJBmIFAMRDYpqjHyDD4wQg16YTScNhn0BBQyBHYE0jnKBSgSFOpNLgTiPMxgpgWmCejuBLiQ
X-IronPort-AV: E=Sophos;i="4.97,926,1389740400"; 
   d="scan'208";a="65825600"
Received: from mail-pd0-f174.google.com ([209.85.192.174])
  by a-mx1.relay.syrhano.net with ESMTP; 25 Apr 2014 12:58:16 +0200
Received: by mail-pd0-f174.google.com with SMTP id z10so2208618pdj.5
        for <bioinfo@sfbi.fr>; Fri, 25 Apr 2014 03:58:14 -0700 (PDT)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
        d=gmail.com; s=20120113;
        h=mime-version:sender:date:message-id:subject:from:to:content-type
         :content-transfer-encoding;
        bh=RZqGlyrXsCdNOcRyW/YTiT7w2n+sSJ5bVGgddKXfWbY=;
        b=BtacjsO7DnkIRVVXlzRwbpOAho4lXpvtCosubOHshxmUCSF19hWubGx3AsB9wC3syJ
         /sShxsJ0h6cQwCerHKRFons5eEYPTJBY5Skdy7EsrdzZuYGw3xotE5G+lu7LYiYgQtRa
         ClyZ403j9VfDZiq9WgmYBLt+K71KWwMNtL6h5MKl4K6S2CP9RtW2G3h39CtBJhgg0P9X
         ljkc0kGL919R/hSglf716lBc6M/q7w3otin8GubAea6OP5TaaQrPLV++9tvmiXQfRoQY
         yEi39prZzGXimtRIgw7Zu3gaOvzB684DlwIiT1AjZcASgHTZnYuvN9cPogRBESWEpV/k
         BIRQ==
MIME-Version: 1.0
X-Received: by 10.66.164.135 with SMTP id yq7mr7043128pab.126.1398423494400;
 Fri, 25 Apr 2014 03:58:14 -0700 (PDT)
Sender: annerezo@gmail.com
Received: by 10.70.135.101 with HTTP; Fri, 25 Apr 2014 03:58:14 -0700 (PDT)
Date: Fri, 25 Apr 2014 12:58:14 +0200
X-Google-Sender-Auth: 3O7Li8htRFRbOdb-tfS8kjd3DhE
Message-ID: <CAA7cQ7sFm-D=JtKwe8J8tOyO8g5edA17b8ps0Xev54+Ceg6U1Q@mail.gmail.com>
From: Anne Poupon <anne@rezo.net>
To: bioinfo@sfbi.fr
Content-Type: text/plain; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
X-Validation-by: laurent.mouchard@univ-rouen.fr
Subject: [bioinfo] [Emploi][=?UTF-8?Q?Th=C3=A8se?=/PhD] Financement de =?UTF-8?Q?th=C3=A8se?=/PhD funding

Contact

Anne Poupon
Biology and Bioinformatics of Signaling Systems
Physiologie de la Reproduction et des comportements
INRA Tours
http://bios.tours.inra.fr
Anne.Poupon@tours.inra.fr


D=C3=A9veloppement d=E2=80=99une m=C3=A9thode de maturation in silico d=E2=
=80=99anticorps

L=E2=80=99utilisation d=E2=80=99anticorps comme agents th=C3=A9rapeutiques =
est actuellement
l=E2=80=99une des pistes les plus prometteuses pour le d=C3=A9veloppement de
nouveaux traitements dans des maladies tr=C3=A8s vari=C3=A9es. Les r=C3=A9c=
epteurs
coupl=C3=A9s aux prot=C3=A9ines G (GPCR) sont impliqu=C3=A9s dans la grande=
 majorit=C3=A9
des processus physiologiques et pathologiques et sont souvent tr=C3=A8s
sp=C3=A9cifiques du type cellulaire dans lequel ils sont exprim=C3=A9s. A ce
titre ils sont la cible de pr=C3=A8s de 40% des m=C3=A9dicaments actuelleme=
nt
sur le march=C3=A9. Ainsi le d=C3=A9veloppement d=E2=80=99anticorps ciblant=
 des GPCR
devrait permettre d=E2=80=99aller vers des strat=C3=A9gies th=C3=A9rapeutiq=
ues
innovantes. Dans un tel processus, la maturation d=E2=80=99anticorps est une
=C3=A9tape n=C3=A9cessaire pour le d=C3=A9veloppement d=E2=80=99un biom=C3=
=A9dicament quand les
anticorps obtenus apr=C3=A8s immunisation ont une affinit=C3=A9 insuffisante
pour leur cible. Actuellement cette maturation se fait par mutagen=C3=A8se
al=C3=A9atoire, et ce processus est long, co=C3=BBteux et parfois incertain.

Depuis plusieurs ann=C3=A9es nous d=C3=A9veloppons une m=C3=A9thode tr=C3=
=A8s performante
d=E2=80=99amarrage prot=C3=A9ine-prot=C3=A9ine, bas=C3=A9e sur la repr=C3=
=A9sentation des
structures de prot=C3=A9ines par des tessellations de Vorono=C3=AF, et util=
isant
des algorithmes d=E2=80=99optimisation num=C3=A9rique pour l=E2=80=99appren=
tissage d=E2=80=99une
fonction de score =C3=A0 partir d=E2=80=99un ensemble de complexes prot=C3=
=A9iques de
structure tridimensionnelle connue. Cette m=C3=A9thode permet de pr=C3=A9di=
re, =C3=A0
partir des structures tridimensionnelles de deux prot=C3=A9ines, la
structure de l=E2=80=99assemblage, et, dans le cas des complexes antig=C3=
=A8ne/
anticorps, les =C3=A9pitopes. Ceci a =C3=A9t=C3=A9 d=C3=A9montr=C3=A9 non s=
eulement sur des
bases de donn=C3=A9es, mais =C3=A9galement sur des exemples concrets, pour
lesquels la validation exp=C3=A9rimentale a =C3=A9t=C3=A9 r=C3=A9alis=C3=A9=
e. Sur cette base,
nous avons initi=C3=A9 le d=C3=A9veloppement d=E2=80=99une m=C3=A9thode per=
mettant de pr=C3=A9dire
l=E2=80=99affinit=C3=A9 entre deux prot=C3=A9ines.

Le premier objectif de la th=C3=A8se sera de poursuivre ces d=C3=A9veloppem=
ents.
Il s=E2=80=99agira d=E2=80=99=C3=A9valuer et de compl=C3=A9ter l=E2=80=99en=
semble des algorithmes
utilis=C3=A9s pour l=E2=80=99apprentissage, ainsi que d=E2=80=99=C3=A9labor=
er une strat=C3=A9gie
permettant, =C3=A0 partir des structures des deux partenaires utilis=C3=A9s,
d=E2=80=99=C3=A9valuer de mani=C3=A8re automatique et syst=C3=A9matique l=
=E2=80=99affinit=C3=A9 de
mutants. Cette m=C3=A9thode sera dans un premier temps valid=C3=A9e sur des
complexes pour lesquels l=E2=80=99affinit=C3=A9 a =C3=A9t=C3=A9 d=C3=A9term=
in=C3=A9e exp=C3=A9rimentalement.
Nous utiliserons pour cela la banque de donn=C3=A9es g=C3=A9n=C3=A9raliste =
SKEMPI
(http://life.bsc.es/pid/mutation_database/).

Dans un deuxi=C3=A8me temps cette m=C3=A9thode sera appliqu=C3=A9e, dans le=
 cadre
plus restreint des complexes anticorps-antig=C3=A8nes, =C3=A0 la maturation=
 in
silico d=E2=80=99anticorps (Ac) qui seront d=C3=A9velopp=C3=A9s dans les pr=
ojets
MODUPHAC et GPCRAb (contre des GPCR) et ARTE-2 (anticorps
anti-gonadotropines). Il s=E2=80=99agira, =C3=A0 partir d=E2=80=99un antico=
rps d=E2=80=99affinit=C3=A9
mod=C3=A9r=C3=A9e, de g=C3=A9n=C3=A9rer in silico des Ac comportant des mut=
ations, en
particulier dans les parties variables (CDR), puis de pr=C3=A9dire leur
affinit=C3=A9 pour leur antig=C3=A8ne (Ag). Les s=C3=A9quences pr=C3=A9dite=
s comme ayant
une meilleure affinit=C3=A9 pour l=E2=80=99Ag seront produites et caract=C3=
=A9ris=C3=A9es
exp=C3=A9rimentalement, y compris l=E2=80=99activit=C3=A9 agoniste ou antag=
oniste.

Comp=C3=A9tences souhait=C3=A9es

Pour cette th=C3=A8se nous recherchons des candidats ayant des
connaissances en informatique (Linux, C/C++, Perl, m=C3=A9thodes
d=E2=80=99apprentissage) et des connaissances en biologie (en particulier
structure des prot=C3=A9ines).

---------------------------------------------------------------------------=
---------------------------------------------------------------------------=
-----------------------------------------------

Design of a method for in silico maturation of antibodies

Using antibodies as therapeutic agents is one of the most promising
leads for the development of new drugs in a wide variety of diseases.
G-protein coupled receptors (GPCR) are playing key-roles in virtually
all physiologic and pathologic processes, and are often specific to
the cellular type they are expressed in. As such they are targeted by
about 40% of marketed drugs. The development of antibodies targeting
GPCRs should consequently lead to innovative therapeutic strategies.
In such a process, antibody maturation is a necessary step leading to
the development of a new drug if the antibodies obtained after
immunization have insufficient affinity for their target. At present,
this maturation is done using random mutagenesis, a time-consuming and
costly process, which outcome is uncertain.

During the last years we have been developing a powerful
protein-protein docking method, based on a representation of protein
structure using Voronoi tessellation and numerical optimisation
methods allowing to learn scoring functions from a learning set of
complexes with known 3D structure. This method allows to predict, from
the structures of two proteins, the interaction regions (epitope and
paratope in the particular case of antibody/antigen complexes) and the
geometry of the complex. The accuracy of this method has been
validated not only on databases, but also experimentally on complexes
recently discovered. Based on this method, we have initiated the
development of a method allowing the prediction of the affinity of the
complex.

The first objective will be to pursue these developments. Algorithms
used for learning docking scoring functions and affinity prediction
will be evaluated and enriched if necessary. A strategy will then be
defined for the automated evaluation of the affinity of mutants. This
method will first be validated on a benchmark of mutants which
affinity for their partner have been experimentally determined (SKEMPI
http://life.bsc.es/pid/mutation_database/).

This method will then be used to improve the affinity of antibodies
for their targets within different projects our group is involved in:
MODUPHAC and GPCRAb (antibodies against GPCRs) and ARTE-2 (antibodies
against gonadotropins). In these projects, we expect to select
antibodies with medium affinities. The maturation method will be used
to generate in silico mutants of the antibodies (Ab), especially with
the variable regions (CDR) and predict their affinity. The mutants
predicted to have the best affinities will be produced and
characterized experimentally, including their agonist or antagonist
activity.

Skills

We are looking for candidates with good skills in computer sciences
(Linux, C/C++, Perl, machine learning) and knowledge in biology
(especially structural biology)
